WHO antiretroviral therapy guidelines 2010 and impact of tenofovir on chronic kidney disease in Vietnamese HIV-infected patients

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Mizushima, Daisuke ^a,b   Tanuma, Junko ^a   Kanaya, Fumihide ^a   Nishijima, Takeshi ^a,b   Gatanaga, Hiroyuki ^a,b   Lam, Nguyen Tien ^c   Dung, Nguyen Thi Hoai ^c   Van Kinh, Nguyen ^c   Kikuchi, Yoshimi ^a   Oka, Shinichi ^a,b  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c National Hospital of Tropical Diseases   (Viet Nam)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CREATININE; LOPINAVIR; TENOFOVIR; ZIDOVUDINE;

ADULT; AGE DISTRIBUTION; ANTIVIRAL THERAPY; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG SAFETY; DRUG USE; ETHNIC GROUP; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRACTICE GUIDELINE; RISK FACTOR; VIETNAMESE; WEIGHT GAIN; WORLD HEALTH ORGANIZATION;

ADENINE; ADULT; ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; RENAL INSUFFICIENCY, CHRONIC; VIETNAM;

EID: 84892383239     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079885     Document Type: Article

References (26)

1. Wyatt CM, Winston JA, Malvestutto CD, Fishbein DA, Barash I et al. (2007) Chronic kidney disease in HIV infection: an urban epidemic. AIDS 21: 2101-2103. doi:10.1097/QAD.0b013e3282ef1bb4. PubMed: 17885301.
2. Mocroft A, Kirk O, Gatell J, Reiss P, Gargalianos P et al. (2007) Chronic renal failure among HIV-1-infected patients. AIDS 21: 1119-1127. doi:10.1097/QAD.0b013e3280f774ee. PubMed: 17502722.
3. Palella FJ Jr., Baker RK, Moorman AC, Chmiel JS, Wood KC et al. (2006) Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 43: 27-34. doi:10.1097/01.qai.0000233310.90484.16. PubMed: 16878047.
4. Michaels SH, Clark R, Kissinger P (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 339: 405-406. doi:10.1056/NEJM199808063390612. PubMed: 9696654.
5. Gardner LI, Klein RS, Szczech LA, Phelps RM, Tashima K et al. (2003) Rates and risk factors for condition-specific hospitalizations in HIV-infected and uninfected women. J Acquir Immune Defic Syndr 34: 320-330. doi:10.1097/00126334-200311010-00011. PubMed: 14600579.
6. Déti EK, Thiébaut R, Bonnet F, Lawson-Ayayi S, Dupon M et al. (2010) Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France. HIV Med 11: 308-317. doi:10.1111/j.1468-1293.2009.00780.x. PubMed: 20002500.
7. Overton ET, Nurutdinova D, Freeman J, Seyfried W, Mondy KE (2009) Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy. HIV Med 10: 343-350. doi:10.1111/j.1468-1293.2009.00693.x. PubMed: 19490182.
8. Lucas GM, Lau B, Atta MG, Fine DM, Keruly J et al. (2008) Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J Infect Dis 197: 1548-1557. doi:10.1086/587994. PubMed: 18422458.
9. Menezes AM, Torelly J Jr., Real L, Bay M, Poeta J et al. (2011) Prevalence and risk factors associated to chronic kidney disease in HIV-infected patients on HAART and undetectable viral load in Brazil. PLOS ONE 6: e26042. doi:10.1371/journal.pone.0026042. PubMed: 22022501.
10. Crum-Cianflone N, Ganesan A, Teneza-Mora N, Riddle M, Medina S et al. (2010) Prevalence and factors associated with renal dysfunction among HIV-infected patients. AIDS Patient Care STDs 24: 353-360. doi:10.1089/apc.2009. 0326. PubMed: 20515419.
11. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D et al. (2010) Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 24: 1667-1678. doi:10.1097/QAD.0b013e328339fe53. PubMed: 20523203.
12. Barrios A, García-Benayas T, González-Lahoz J, Soriano V (2004) Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS 18: 960-963. doi:10.1097/00002030-200404090-00019. PubMed: 15060449.
13. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S et al. (2010) Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 51: 496-505. doi:10.1086/655681. PubMed: 20673002.
14. Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B et al. (2007) The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 21: 1273-1281. doi: 10.1097/QAD. 0b013e3280b07b33. PubMed: 17545703.
15. Chaisiri K, Bowonwatanuwong C, Kasettratat N, Kiertiburanakul S (2010) Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight. Curr HIV Res 8: 504-509. doi:10.2174/157016210793499259. PubMed: 21073439.
16. Nishijima T, Komatsu H, Gatanaga H, Aoki T, Watanabe K et al. (2011) Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLOS ONE 6: e22661. doi:10.1371/journal.pone.0022661. PubMed: 21799928.
17. Nishijima T, Gatanaga H, Komatsu H, Tsukada K, Shimbo T et al. (2012) Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naive patients with HIV infection. PLOS ONE 7: e29977. doi:10.1371/journal.pone.0029977. PubMed: 22242194.
18. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39: S1-266. doi:10.1053/ajkd.2002.30571. PubMed: 11904577.
19. Ito J, Dung DT, Vuong MT, Tuyen do G, Vinh le D et al. (2008) Impact and perspective on chronic kidney disease in an Asian developing country: a large-scale survey in North Vietnam. Nephron Clin Pract 109: c25-c32. doi:10.1159/000134379. PubMed: 18497502.
20. Van Rompay KK, Durand-Gasselin L, Brignolo LL, Ray AS, Abel K et al. (2008) Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 52: 3144-3160. doi:10.1128/AAC.00350-08. PubMed: 18573931.
21. Gallant JE, Moore RD (2009) Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS 23: 1971-1975. doi:10.1097/QAD.0b013e32832c96e9. PubMed: 19696652.
22. Wever K, van Agtmael MA, Carr A (2010) Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr 55: 78-81. doi:10.1097/QAI.0b013e3181d05579. PubMed: 20173649.
23. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK (2002) Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations Panel Clinical Practices Treat HIV MMWR Recomm Rep 51: 1-55. PubMed: 12617573.
24. Stevens LA, Levey AS (2005) Measurement of kidney function. Med Clin North Am 89: 457-473. doi:10.1016/j.mcna.2004.11.009. PubMed: 15755462.
25. Stöhr W, Walker AS, Munderi P, Tugume S, Gilks CF et al. (2008) Estimating glomerular filtration rate in HIV-infected adults in Africa: comparison of Cockcroft-Gault and Modification of Diet in Renal Disease formulae. Antivir Ther 13: 761-770. PubMed: 18839777.
26. Soares AA, Eyff TF, Campani RB, Ritter L, Weinert LS et al. (2010) Performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations in healthy South Brazilians. Am J Kidney Dis 55: 1162-1163. doi:10.1053/j.ajkd.2010.03.008. PubMed: 20497836.